Journey Medical Corp (DERM) stock

DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% below fair value

$4.33−0.06 (-1.37%)

Close on Nov 13, 2026Market cap $122.21MP/E –Yield –

Journey Medical EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Journey Medical's EV/EBITDA was 51.8× on Oct 31, 2024.

Period	Period end	Value	Change (pts)
2024	Oct 31, 2024	51.8×	–

Parsed from the XBRL in Journey Medical's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DERM.

Revenue growth17.0% · median -4.0%

Gross margin65.9% · median 64.0%

Operating margin-2.9% · median -14.4%

Net margin-7.3% · median -12.7%

Advertisement
300 × 250

See a number that looks wrong?